Five Mutual Fund Houses Receive ₹104 Crore Allocation in Sahajanand Medical Technologies IPO

Key Takeaways:

• Five domestic mutual fund houses received approximately ₹104 crore worth of shares through seven schemes in Sahajanand Medical Technologies' IPO anchor allocation. 
• The company raised ₹140.06 crore from anchor investors through the allotment of approximately 40.71 lakh shares at ₹344 each. 
• Sahajanand Medical Technologies' ₹475.48 crore IPO closed for subscriptions on 19 October 2026 and consisted entirely of an offer for sale. 

Domestic Mutual Funds Participate in Anchor Allocation 

Five domestic mutual fund houses collectively received approximately ₹104 crore worth of shares in the anchor investor allocation for Sahajanand Medical Technologies' initial public offering. 

The allotment took place on 14 October 2026, ahead of the public issue opening on 15 October. 

The participating mutual fund houses were Nippon India Mutual Fund, DSP Mutual Fund, WhiteOak Capital Mutual Fund, Invesco Mutual Fund and UTI Mutual Fund. 

They participated through seven mutual fund schemes and received approximately 30.25 lakh equity shares. 

The allocation represented a large portion of the shares distributed through the company's anchor book. 

Anchor Investors Receive Shares Worth ₹140.06 Crore 

Sahajanand Medical Technologies raised approximately ₹140.06 crore from eight anchor investors. 

The company allotted approximately 40.71 lakh equity shares at ₹344 per share, the upper end of the IPO price band. 

Of these shares, approximately 30.25 lakh were allotted to domestic mutual fund schemes. 

The mutual fund allocation represented roughly three-quarters of the total anchor shares. 

Other participants included Allianz Global Investors Fund, Tata AIA Life Insurance Company and Natixis International Funds. 

Anchor investors are institutional participants who receive an allocation before an IPO opens for public subscription, subject to the applicable regulatory conditions. 

The allocation provides information about institutional participation in a public issue but does not establish the eventual performance of the company's listed shares. 

Sahajanand Medical Technologies IPO Details 

The public issue was structured entirely as an offer for sale involving approximately 1.38 crore equity shares. 

Under this structure, the proceeds from shares sold through the IPO go to the selling shareholders after applicable expenses, rather than providing fresh capital to the company. 

Company Operates in Medical Devices 

Sahajanand Medical Technologies develops and manufactures medical devices used in vascular intervention and structural heart procedures. 

Its product range includes coronary stents, coronary balloons and devices used in structural heart treatments. 

The company also offers other specialised medical products, including renal stents and peripheral drug-coated balloons. 

Its business operates in a segment where product quality, clinical requirements and regulatory approvals form important parts of commercial operations. 

Mutual Fund Allocation Provides Institutional Participation Data 

The participation of seven mutual fund schemes provides a measurable example of domestic institutional involvement in the IPO market. 

Different schemes may participate in anchor allocations under their respective investment mandates and portfolio frameworks. 

The amount allotted to mutual funds is distinct from the total IPO subscription figure. 

The anchor allocation was completed before the public bidding period, while the IPO entered its final subscription day on 19 October. 

The reported ₹104 crore allocation is a factual record of institutional participation and should not be interpreted as an indication of future listing returns.